Automated Insulin Delivery with GLP-1 Dose-Based Insulin Reduction
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Conventional automatic insulin delivery (AID) systems over-deliver insulin when GLP-1 receptor agonists are administered, leading to potential hypoglycemia and weight gain, as they do not account for the insulin-reducing effects of GLP-1.
Innovation Solution
Incorporating GLP-1 and insulin co-formulations in AID systems, adjusting insulin delivery algorithms to consider the insulin-reducing effects of GLP-1 by calculating a reduction factor based on GLP-1 dosage, modifying insulin-to-carbohydrate ratio and correction factor to optimize insulin delivery.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If conventional AID systems deliver insulin using standard algorithms, then glucose control is maintained, but insulin over-delivery occurs when GLP-1 is administered, leading to hypoglycemia and weight gain
Solution Approach 1:
The system dynamically adjusts insulin delivery parameters by calculating a reduction factor based on GLP-1 dosage. When GLP-1 is detected in the co-formulation, the algorithm modifies the insulin-to-carbohydrate ratio and correction factor parameters, reducing insulin delivery by the calculated reduction factor to prevent hypoglycemia and weight gain while maintaining glucose control
Solution Approach 2:
The system incorporates feedback from GLP-1 administration by monitoring the co-formulation composition and adjusting insulin delivery algorithms accordingly. The reduction factor calculation provides continuous feedback to the control algorithm, enabling real-time adaptation to GLP-1's insulin-sensitizing effects
2Quantity of substance
If GLP-1 and insulin co-formulation is used, then overall insulin requirements are reduced, but the AID algorithm must be updated to account for GLP-1's insulin-reducing effects
Solution Approach 1:
The system manages algorithm complexity by focusing on parameter adjustments rather than complete algorithm redesign. Key parameters including insulin-to-carbohydrate ratio, correction factor, and reduction factor are dynamically modified based on GLP-1 dosage, allowing the system to handle co-formulation without requiring fundamental algorithmic changes
Solution Approach 2:
The algorithm is segmented into distinct calculation components: GLP-1 dosage detection, reduction factor calculation, and insulin delivery adjustment. This modular approach allows the system to process GLP-1 effects separately from standard insulin delivery algorithms, reducing overall system complexity
Data Source
AI summary
Disclosed herein are systems and methods for the delivery of a co-formulation of insulin and a second drug, such as GLP-1, using an automated insulin delivery system. In a first embodiment, a dose of insulin is calculated by a medication delivery algorithm and a reduction factor is applied to account for the effect of second drug on the user's daily insulin requirement. In a second embodiment of the invention, a total amount of the second drug administered to the user during the past 24 hours is used to modify the correction factor and the insulin-to-carbohydrate ratio used by the medication delivery algorithm to cause a reduction in the insulin delivered to the user to account for the effect of the administration of the second drug portion of the co-formulation.